Minimally Invasive Heart Transport-B (02160): VitaFOW® series transcatheter aortic valves and delivery systems have entered 35 countries and regions around the world, with a cumulative total of nearly 1,300 implants

Zhitong Finance App News, Minimally Invasive Xintong-B (02160) issued an announcement. As of the date of this announcement, the Group's VitaFOW® series transcatheter aortic valves and delivery systems have entered 35 countries and regions around the world, with a cumulative total of nearly 1,300 implants. Among them, the number of implants is expected to exceed 850 in 2025, an increase of nearly 350% over 2024. In the second half of 2025, thanks to the continued expansion of commercialization of VitaFow Liberty® in European countries after obtaining CE certification, and the continued increase in the share of emerging markets in Asia and Latin America, implantation volume increased by more than 170% compared to the first half of the year.

The board of directors of the company believes that through the recently completed merger and acquisition of minimally invasive heart rhythm management transactions, the group will further strengthen the localized channel resources and clinical support system in mature markets such as Europe, and significantly improve the efficiency of TAVI products entering new markets and the depth of penetration into existing markets. In the future, the Group will continue to unleash the potential for collaboration after business integration, continue to advance the development and clinical progress of next-generation TAVI products, further improve overall structural heart disease solutions, and comprehensively enhance the Group's comprehensive competitiveness in the field of global valve treatment.